TRIB (Trinity Biotech) 3-Year RORE % : -25.00% (As of Dec. 2025)


TRIB Trinity Biotech PLC TRIB
28 GF Score
Price $0.37
GF Value $0.74
Valuation Possible Value Trap
! 7 Warning Signs
View Full Analysis

What is Trinity Biotech 3-Year RORE %?

Trinity Biotech TRIB +6.30% 28 3-Year RORE % is -25.00 as of Dec. 2025. GuruFocus rates TRIB with a GF Score™ of 28/100 and a GF Value™ of $0.74 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 782 Medical Devices & Instruments companies, Trinity Biotech ranks worse than 69.95% on this metric.

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Trinity Biotech's 3-Year RORE % for the quarter that ended in Dec. 2025 was -25.00%.

The industry rank for Trinity Biotech's 3-Year RORE % or its related term are showing as below:

TRIB's 3-Year RORE % is ranked worse than
69.95% of 782 companies
in the Medical Devices & Instruments industry
Industry Median: -4.23 vs TRIB: -25.00

Trinity Biotech  (NAS:TRIB) 3-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Trinity Biotech 3-Year RORE % Related Terms


Trinity Biotech 3-Year RORE % Historical Data

* Premium members only.

The historical data trend for Trinity Biotech's 3-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Trinity Biotech 3-Year RORE % Chart

Trinity Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
3-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -85.71 59.46 42.86 -33.33 -25.00

Trinity Biotech Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
3-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 42.86 -2.73 -33.33 -21.90 -25.00

TRIB vs AIDX, NVNO, STME: 3-Year RORE % Comparison

For the Medical Devices subindustry, Trinity Biotech's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Trinity Biotech 3-Year RORE % vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Trinity Biotech's 3-Year RORE % distribution charts can be found below:

* The bar in red indicates where Trinity Biotech's 3-Year RORE % falls into.


TRIB
28GF Score
Trinity Biotech PLC TRIB
3-Year RORE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Trinity Biotech 3-Year RORE % Calculation

Trinity Biotech's 3-Year RORE % for the quarter that ended in Dec. 2025 is calculated as:

3-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 3-year -Cumulative Dividends per Share for 3-year )
=( -2--4 )/( -8-0 )
=2/-8
=-25.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Dec. 2025 and 3-year before.

Frequently Asked Questions Learn more about 3-Year RORE % →
What does a 3-Year RORE % of -25.00 mean?
Trinity Biotech (TRIB) has a 3-Year RORE % of -25.00 as of Dec. 2025. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Trinity Biotech and its competitors. According to the industry distribution chart, Trinity Biotech ranks #547 out of 782 companies in the Medical Devices & Instruments industry, placing it in the top 69.9%.
Is Trinity Biotech's 3-Year RORE % too high?
Trinity Biotech's current 3-Year RORE % is -25.00. Based on the distribution chart, Trinity Biotech ranks #547 out of 782 companies in the Medical Devices & Instruments industry, which is below the industry midpoint. Overall, Trinity Biotech has a GF Score™ of 28/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Trinity Biotech's 3-Year RORE % compare to AIDX and NVNO?
According to the Medical Devices & Instruments industry distribution chart, Trinity Biotech ranks #547 out of 782 companies for 3-Year RORE %. This places Trinity Biotech in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Devices & Instruments company?
A good 3-Year RORE % depends on the Medical Devices & Instruments industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Trinity Biotech and its competitors. Trinity Biotech's current 3-Year RORE % is -25.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Trinity Biotech stock overvalued right now?
Based on GuruFocus' analysis, Trinity Biotech (TRIB) is currently considered Possible Value Trap. The stock's GF Value™ is $0.74, compared to a current price of $0.37 — trading 50.1% below its estimated fair value. The current 3-Year RORE % is -25.00. Trinity Biotech's overall GF Score™ is 28/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Trinity Biotech (TRIB), the current 3-Year RORE % is -25.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Trinity Biotech (TRIB) Overvalued in 2026?

Based on GuruFocus' analysis, Trinity Biotech stock appears to be undervalued. The current stock price of $0.37 is trading 50.1% below its estimated GF Value™ of $0.74. GuruFocus considers Trinity Biotech to be Possible Value Trap.

Key valuation signals for TRIB:

  • 3-Year RORE %: -25.00
  • GF Value™: $0.74 vs. price of $0.37 (50.1% below fair value)
  • GF Score™: 28/100 with 7 warning signs

No single metric tells the full story. See the TRIB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Trinity Biotech Business Description

Address IDA Business Park, Bray, County Wicklow, Dublin, IRL, A98 H5C8
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has three segments, namely the Americas, Asia/Africa, and Europe, from which it derives a majority of its revenue from the Americas segment.
28GF Score

Get the complete analysis for TRIB

3-Year RORE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.37
Price
$0.74
GF Value